Coherus BioSciences Provides Update on ‘619 IPR Institution Decision
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
IPR Decision Disappointing for Coherus Biosciences (CHRS) But Focus Remains on Neulasta - Cowen
September 7, 2017 1:46 PM EDTCowen analyst Ken Cacciatore weighs in on Coherus Biosciences (NASDAQ: CHRS) following an adverse IPR decision on the Humira '619 patents.
Cacciatore said while this is disappointing, their focus remains on biosimilar Neulasta and the hopeful year-end BLA re-filing.
The firm... More
